31P - Serum tumor markers CEA, CYFRA 21-1 and anti-p53 in patients with lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Franco Lumachi
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F. Lumachi1, F. Mazza2, A. Del Conte3, G.B. Chiara4, S.M.M. Basso4
  • 1Department Of Surgery, Oncology & Gastroenterology, University of Padua, School of Medicine, 35128 - Padova/IT
  • 2Pneumology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 3Medical Oncology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 4Surgery 1, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT


Lung cancer is one of the most common neoplasms throughout the world, and the most devasting cause of cancer-related death. The 5-year survival rate is very low, accounting for approximately 15%, and it has changed minimally over the past 25 years (1). The poor survival is attrubutable to the fact that the majority of cases are diagnosed when the disease is already metastatic. At this stage, the therapeutic options are restricted to palliative systemic chemotherapy or radiation therapy. Only for patients diagnosed and treated at early stage (Stage I) the 5-year survival is relatively good, ranging between 50% and 80% (2). Several serum tumor markers have been tested in patients with lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1), squamous cell carcinoma antigen, neuron-specific enolase (NSE), and more recently anti-p53 antibody circulating markers. The aim of this study was to evaluate the usefulness of serum CEA, CYFRA 21-1, and anti-p53 assay in patents with lung cancer.